Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01848041 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy Study of RVL-1201 in Acquired Blepharoptosis
A Phase 1 study, sponsored by RVL Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT01848041 is a Phase 1 study that has completed, run by RVL Pharmaceuticals. The registered enrollment target is 46 participants.
The verdict
NCT01848041, a Phase 1 study, has completed, sponsored by RVL Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
This is an exploratory, proof of concept study to evaluate the safety and efficacy of RVL-1201 dosed once or twice daily for 14 days compared to a placebo (vehicle) control in patients with ptosis.
Interventions
- DRUG RVL-1201
- DRUG RVL-1201 Vehicle Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2013-05 |
| Est. Completion | 2014-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01848041
The ClinicalTrials.gov registry entry for NCT01848041 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is RVL Pharmaceuticals, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which RVL-1201 is the first listed.
NCT01848041 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01848041 about?
NCT01848041 is a clinical study titled "Safety and Efficacy Study of RVL-1201 in Acquired Blepharoptosis". This is an exploratory, proof of concept study to evaluate the safety and efficacy of RVL-1201 dosed once or twice daily for 14 days compared to a placebo (vehicle) control in patients with ptosis.
What is the current status of trial NCT01848041?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2013-05. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01848041?
The interventions under investigation include: RVL-1201 (DRUG), RVL-1201 Vehicle Placebo (DRUG).
Who is sponsoring clinical trial NCT01848041?
This trial is sponsored by RVL Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.